Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.

Abstract

Objectives: Incorporating CD40 ligand (CD40L) into vaccine strategies has shown considerable potential for enhancing immune responses. In this study, we designed and formulated a CD40L-based multi-epitope vaccine construct using immunoinformatics approaches, and compared it to a full-length CD40L-based vaccine construct.

Methods: The study commenced with the identification and screening of potential T-cell and B-cell epitopes derived from the CD40L protein, followed by the construction of a multi-epitope vaccine from these selected epitopes. We analyzed and validated the physicochemical and structural properties of the vaccine constructs. Further, we predicted disulfide bonds, performed protein-protein docking, and conducted molecular dynamics simulations to evaluate the constructs. Comparative analyses of the ligand-binding site localization were conducted using LigPlot. Additionally, simulation trajectories were analyzed using multiple descriptors, including root mean square deviations, radius of gyration, and root mean square fluctuations.

Results: Our findings indicated that the CD40L multi-epitope vaccine construct possessed favorable physicochemical properties and a validated structural profile. Immune simulation studies showed a stronger affinity of the multi-epitope construct for the CD40 receptor compared to the full-length CD40L construct.

Conclusion: Overall, the CD40L multi-epitope vaccine construct demonstrated greater potency in eliciting an effective immune response than the full-length CD40L construct. These results highlight a promising approach to vaccine design for the prevention or treatment of infections and cancers.